Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review (Q37547456)

20 August 2017

1 reference

title

Management of women with uterine papillary serous cancer: a Society of Gynecologic Oncology (SGO) review (English)

1 reference

20 August 2017

1 reference

2

Paola A Gehrig

1 reference

20 August 2017

David M Boruta

1

1 reference

20 August 2017

Amanda Nickles Fader

series ordinal

3

1 reference

20 August 2017

Alexander B Olawaiye

series ordinal

4

1 reference

20 August 2017

language of work or name

English

0 references

publication date

9 July 2009

1 reference

20 August 2017

1 reference

20 August 2017

volume

115

1 reference

20 August 2017

issue

1

1 reference

20 August 2017

page(s)

142-153

1 reference

20 August 2017

cites work

Cancer statistics, 2008

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Trends in demographic and clinical characteristics in women diagnosed with corpus cancer and their potential impact on the increasing number of deaths.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Epidemiologic and surgicopathologic findings of papillary serous and clear cell endometrial cancers when compared to endometrioid carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine papillary serous and clear cell carcinomas predict for poorer survival compared to grade 3 endometrioid corpus cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Two pathogenetic types of endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Body size in relation to cancer of the uterine corpus in 1 million Norwegian women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Body Mass and Endometrial Cancer Risk by Hormone Replacement Therapy and Cancer Subtype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

The effect of age on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Papillary serous and clear cell type lead to poor prognosis of endometrial carcinoma in black women

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Analysis of racial differences in incidence, survival, and mortality for malignant tumors of the uterine corpus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Racial disparity in survival among patients with advanced/recurrent endometrial adenocarcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Racial disparities in blacks with gynecologic cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Clinicopathologic analysis of 187 high-grade endometrial carcinomas of different histologic subtypes: similar outcomes belie distinctive biologic differences

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Endometrial intraepithelial carcinoma: a distinctive lesion specifically associated with tumors displaying serous differentiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine serous carcinoma. A morphologically diverse neoplasm with unifying clinicopathologic features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Endometrial glandular dysplasia and endometrial intraepithelial neoplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Occurrence of endometrial glandular dysplasia precedes uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Endometrial glandular dysplasia: a newly defined precursor lesion of uterine papillary serous carcinoma. Part I: morphologic features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Molecular and pathologic aspects of endometrial carcinogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

p53 overexpression and bcl-2 persistence in endometrial carcinoma: comparison of papillary serous and endometrioid subtypes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Is Uterine Papillary Serous Adenocarcinoma a Manifestation of the Hereditary Breast–Ovarian Cancer Syndrome?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

BRCA germline mutations in Jewish women with uterine serous papillary carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Risk of Endometrial Carcinoma Associated with BRCA Mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Patients having prophylactic surgery for family history or known genetic mutations: why save the uterus?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Comprehensive Cancer Centres' ALERT Group. Assessment of Liver and Endometrial cancer Risk following Tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Association between uterine serous carcinoma and breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Iatrogenic risks of endometrial carcinoma after treatment for breast cancer in a large French case-control study. Fédération Nationale des Centres de Lutte Contre le Cancer (FNCLCC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Outcomes in patients with primary breast cancer and a subsequent diagnosis of endometrial cancer : comparison of cohorts treated with and without tamoxifen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Breast cancer followed by corpus cancer: is there a higher risk for aggressive histologic subtypes?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Papillary serous carcinoma of the uterus: increased risk of subsequent or concurrent development of breast carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine papillary serous carcinoma (UPSC): a single institution review of 129 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Is there a difference in outcome between stage I-II endometrial cancer of papillary serous/clear cell and endometrioid FIGO Grade 3 cancer?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine serous and grade 3 endometrioid carcinomas: is there a survival difference?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Her-2/neu overexpression and amplification in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Stage IA uterine serous carcinoma: a study of 13 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine papillary serous carcinoma: patterns of metastatic spread

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Minimal uterine serous carcinoma: diagnosis and clinicopathologic correlation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Serous EIC as an early form of uterine papillary serous carcinoma: recent progress in understanding its pathogenesis and current opinions regarding pathologic and clinical management

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Accuracy of preoperative endometrial sampling for the detection of high-grade endometrial tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Thin endometrial echo complex on ultrasound does not reliably exclude type 2 endometrial cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Transvaginal sonography of the endometrium in women with postmenopausal bleeding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Complete response of a stage IV uterine papillary serous carcinoma to neoadjuvant chemotherapy with Taxol and carboplatin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Complete clinical responses to neoadjuvant chemotherapy for uterine serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Neoadjuvant chemotherapy in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Therapeutic role of lymph node resection in endometrioid corpus cancer: a study of 12,333 patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (MRC ASTEC trial): a randomised study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine papillary serous carcinoma: a study on 108 cases with emphasis on the prognostic significance of associated endometrioid carcinoma, absence of invasion, and concomitant ovarian carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Minimal uterine serous carcinoma: a clinicopathological study of 40 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Significance of comprehensive surgical staging in noninvasive papillary serous carcinoma of the endometrium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Effective Treatment of Stage I Uterine Papillary Serous Carcinoma with High Dose-Rate Vaginal Apex Radiation (192Ir) and Chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

What staging surgery should be performed on patients with uterine papillary serous carcinoma?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

The role of omentectomy during the surgical staging of uterine serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

The role of cytoreductive surgery in the management of stage IV uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Stage IVB endometrial carcinoma: the role of cytoreductive surgery and determinants of survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

The Role of Surgical Cytoreduction in Stage IV Endometrial Carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Optimal surgical cytoreduction in patients with Stage III and Stage IV endometrial carcinoma: a study of morbidity and survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

FIGO stage III and IV uterine papillary serous carcinoma: impact of residual disease on survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

The role of optimal debulking in advanced stage serous carcinoma of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Role of cytoreduction in stage III and IV uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Patterns of failure after the multimodality treatment of uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

The role of abdominal-pelvic radiotherapy in the management of uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Improved outcome at 10 years for serous-papillary/clear cell or high-risk endometrial cancer patients treated by adjuvant high-dose whole abdomino-pelvic irradiation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Outcome and pattern of failure in pathologic stage I–II papillary serous carcinoma of the endometrium: Implications for adjuvant radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Adjuvant whole abdominal irradiation in clinical stages I and II papillary serous or clear cell carcinoma of the endometrium: a phase II study of the Gynecologic Oncology Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine papillary serous carcinoma: comparisons of outcomes in surgical Stage I patients with and without adjuvant therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Intraperitoneal radioactive phosphorus (32P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: a phase II Hoosier Oncology Group (HOG 97-01) study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

The efficacy of adjuvant platinum-based chemotherapy in Stage I uterine papillary serous carcinoma (UPSC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Outcomes in surgical stage I uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Role of systematic lymphadenectomy and adjuvant therapy in stage I uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Pilot phase II trial of radiation "sandwiched" between combination paclitaxel/platinum chemotherapy in patients with uterine papillary serous carcinoma (UPSC).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

High-dose rate brachytherapy for Stage I/II papillary serous or clear cell endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Optimal management for surgically Stage 1 serous cancer of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine papillary serous carcinoma: evaluation of long-term survival in surgically staged patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Impact of adjuvant therapy on survival of patients with early-stage uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Is adjuvant therapy necessary for stage IA and IB uterine papillary serous carcinoma and clear cell carcinoma after surgical staging?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Preoperative radiation therapy in clinical stage II endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Treatment of high-risk uterine cancer with whole abdominopelvic radiation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Whole abdominal radiotherapy in the adjuvant treatment of patients with stage III and IV endometrial cancer: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine papillary serous carcinoma (UPSC) treated with cisplatin, doxorubicin, and cyclophosphamide (PAC)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Intravenous cisplatin, doxorubicin, and cyclophosphamide in the treatment of uterine papillary serous carcinoma (UPSC)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Randomized Phase III Trial of Standard Timed Doxorubicin Plus Cisplatin Versus Circadian Timed Doxorubicin Plus Cisplatin in Stage III and IV or Recurrent Endometrial Carcinoma: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a gynecologic oncology group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

The use of paclitaxel and platinum-based chemotherapy in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Treatment of uterine papillary serous carcinoma with paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Paclitaxel and carboplatin, alone or with irradiation, in advanced or recurrent endometrial cancer: a phase II study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Paclitaxel and carboplatin in the adjuvant treatment of patients with high-risk stage III and IV endometrial cancer: a retrospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Carboplatin and paclitaxel in advanced or metastatic endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine papillary serous carcinoma treated with intraperitoneal cisplatin and intravenous doxorubicin and cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine serous carcinoma: a comparison of therapy for advanced-stage disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

The effect of adjuvant chemotherapy versus whole abdominopelvic radiation on the survival of patients with advanced stage uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine papillary serous carcinoma. A clinical study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Outcome after combined modality treatment for uterine papillary serous carcinoma: a study by the Rare Cancer Network (RCN).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Randomized Phase III Trial of Whole-Abdominal Irradiation Versus Doxorubicin and Cisplatin Chemotherapy in Advanced Endometrial Carcinoma: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Adjuvant sequential chemotherapy and radiotherapy in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

A pilot trial of TAC (paclitaxel, doxorubicin, and carboplatin) chemotherapy with filgastrim (r-metHuG-CSF) support followed by radiotherapy in patients with "high-risk" endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Serum CA-125 as a marker of disease activity in uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

CA 125 may not reflect disease status in patients with uterine serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Elevation of serum CA125 in carcinomas of the fallopian tube, endometrium, and endocervix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

CA 125: a useful marker in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Predictive value of preoperative serum CA 125 levels in clinically localized and advanced endometrial carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Value of Preoperative CA 125 Level in the Management of Uterine Cancer and Prediction of Clinical Outcome

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Utility of pre-operative serum CA-125 in the management of uterine papillary serous carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Preoperative serum YKL-40 is a marker for detection and prognosis of endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine papillary serous carcinoma: what have we learned over the past quarter century?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine papillary serous carcinomas: the exigency for clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

Uterine papillary serous carcinoma: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Recurrence in noninvasive endometrial carcinoma. Relationship to uterine papillary serous carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2009.06.011

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.YGYNO.2009.06.011

1 reference

20 August 2017

1 reference